Year : 2015  |  Volume : 6  |  Issue : 3  |  Page : 147-153

The effects of A2B receptor modulators on vascular endothelial growth factor and nitric oxide axis in chronic cyclosporine nephropathy

1 Department of Pharmacology, Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology, Anand, Gujarat, India
2 Department of Pharmacology and Toxicology, College of Veterinary Science and Animal Husbandry, Anand Agricultural University, Anand, Gujarat, India

Correspondence Address:
Leena Patel
Department of Pharmacology, Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology, Charusat Campus, Changa - 388 421, Taluka - Petlad, District - Anand, Gujarat
Login to access the Email id

Source of Support: Nil, Conflict of Interest: None declared.

DOI: 10.4103/0976-500X.162014

Rights and Permissions

Introduction: To investigate the actions of adenosine A2B receptor modulators on VEGF and NO levels in CsA nephropathy. Materials and Methods: Nephropathy was induced by administrating 25 mg/kg (s.c) of CsA for 5 weeks. The VEGF and NO levels were measured in kidney tissue. Serum creatinine, creatinine clearance, urinary albumin excretion, blood urea nitrogen, kidney pathology score were measured to assess renal function. The analysis of mRNA expression of A2B receptor and VEGF was performed. Results: Administration of CsA for 5 weeks induced adverse renal function. The mRNA expression of VEGF was reduced in renal tissue after 5 weeks of CsA treatment. The renal VEGF and NO levels were also reduced in these animals. In vivo administration of A2B adenosine receptor agonist increased renal VEGF which was inhibited by a selective A2BAR antagonist (MRS1754) in CsA-treated animals. The increase in VEGF was associated with reversal of adverse renal functions. The effects of A2BAR modulators were prominent in CsA-treated animals compared with control animals suggesting CsA treatment may upregulate A2BARs. The mRNA expression of A2BAR was increased after 5 weeks of CsA. Conclusions: A2BAR modulators may provide new therapeutic options to retard CsA nephropathy by mediating renal VEGF and NO.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded307    
    Comments [Add]    
    Cited by others 2    

Recommend this journal